• Integrated DNA Technologies Introduces Transformative Hybridization Capture Solution to Accelerate Cancer Research

    Apr 22, 2025, 08:15 AM by
    New xGen™ hybridization and wash offering is poised to revolutionize targeted next generation sequencing workflows
    Full story
  • Symbiosis Earns Recognition from EcoVadis for Commitment to Sustainability

    Apr 22, 2025, 08:15 AM by
    Symbiosis Pharmaceutical Services, a specialist sterile manufacturing CMO, who has been formally recognised by EcoVadis for its continued commitment to sustainability.
    Full story
  • AI in Drug Development: Promise and Pitfalls

    Apr 22, 2025, 01:00 AM by User Not Found
    Bio-IT World | An expert panel of technology and pharmaceutical executives convened at this month's Bio-IT World Venture, Innovation, and Partnering event to discuss the transformative potential of artificial intelligence in drug development—and the significant challenges that still lie ahead. Participants included Rory Kelleher of NVIDIA, Bill Fitzgerald from Google Cloud, Bill Mayo of Bristol-Myers Squibb, Anthony Philippakis of GV (formerly Google Ventures), and Becky Stevenson of HSBC, moderated by Jeremy Goldberg of Arsenal Capital Partners.
    Full story
  • Insilico’s Alex Zhavoronkov Highlights Generative AI's Impact on Drug Discovery and Aging Research

    Apr 17, 2025, 01:00 AM by User Not Found
    Bio-IT World | At the Bio-IT World Conference & Expo earlier this month, Alex Zhavoronkov, CEO and founder of Insilico Medicine, shared the company's progress in leveraging generative AI to accelerate drug discovery, particularly focusing on aging research. Celebrating the company's 11th year, Zhavoronkov emphasized his singular mission: helping people live longer, healthier lives.
    Full story
  • CluePoints’ Technology Named as Finalist in 2025 Citeline Awards

    Apr 16, 2025, 06:40 AM by
    CluePoints, provider of leading statistical and AI-driven software solutions, has been named as a finalist in the ‘Innovative Clinical Trial Solutions’ category at the 2025 Citeline Awards.
    Full story
  • VieCure Integrates NCCN Content into Leading Technology Platform for Community Oncology Care

    Apr 16, 2025, 06:40 AM by
    VieCure is making thousands of the most commonly used NCCN Chemotherapy Order Templates available on its Halo Intelligence Platform.
    Full story
  • AI Continues to Make Strides on Therapeutics and Research Progress

    Apr 16, 2025, 01:00 AM by User Not Found
    Bio-IT World | During the final plenary keynote of this year’s Bio-IT World Conference & Expo, we heard from Tris Dyson, Challenge Works, and Jeffrey Rothstein, Johns Hopkins University; Robert Green, Harvard Medical School; and Justin Scheer, Johnson & Johnson Innovative Medicine. They all gave presentations that highlighted artificial intelligence (AI) and machine learning’s (ML) ever-growing roles in research and healthcare, as well as the impact they have on the future of patient treatment, drug development, and more.
    Full story
  • Meribel Pharma Solutions launches with big ambitions to elevate pharma services to new heights

    Apr 15, 2025, 06:35 AM by
    The launch of a new mid-sized CDMO, Meribel Pharma Solutions, bringing together 10 manufacturing sites and 3 development centres across Europe. The team – including ex-Synerlab and Catalent leadership – aims to offer agile, high-quality solutions across OSD, sterile, and semi-solid manufacturing. Built on a strong legacy, the company is filling a much-needed niche in the market with centres of excellence in lyophilisation, preservative-free multidose tech, and more.
    Full story
  • Oxford Nanopore Expands Compatible Products Programme and Strengthens Multi-Omics Ecosystem

    Apr 15, 2025, 06:35 AM by
    Oxford Nanopore Technologies announced the expansion of its Compatible Products Program. New participating companies include: 10x Genomics, Agilent Technologies, Asuragen, Day Zero Diagnostics, Hamilton Robotics, NEB, Opentrons, Pathosense, and Thermo Fisher Scientific.
    Full story
  • Derek Lowe on AI in Drug Discovery: Between Hype and Hope

    Apr 15, 2025, 01:00 AM by User Not Found
    Bio-IT World | At last week’s Venture, Innovation, and Partnering Summit at the Bio-IT World Conference & Expo, Derek Lowe, Director, Chemical Biology & Therapeutics at Novartis BioMedical Research, and John Keilty, venture partner at Third Rock Ventures, sat down for a candid conversation on the pharmaceutical industry and the current state of artificial intelligence and machine learning (AI/ML) in drug discovery.
    Full story
  • Nuclera expands eProtein Discovery capabilities to enable membrane protein production

    Apr 14, 2025, 12:57 PM by
    ● Membrane proteins synthesized and purified within 48 hours. ● Active membrane transporter, MsbA and integral membrane protein, ZMPSTE24 synthesized
    Full story
  • Innovative Blood Testing Tech Could Spell the End of Needle Phobia

    Apr 11, 2025, 08:06 AM by
    Full story
  • Evestia Clinical’s Bold New Chapter in Oncology and Rare Disease Research

    Apr 11, 2025, 08:06 AM by
    EMAS Pharma has officially rebranded as Evestia Clinical, signaling a bold new chapter as a specialised Contract Research Organization (CRO) dedicated to oncology and rare disease clinical trials. With the backing of Kester Capital and a leadership team with a proven track record, Evestia Clinical is set to redefine the clinical research landscape by delivering agile, expert-driven solutions to biotech innovators worldwide. With a rapidly growing demand for faster, more adaptive trials in complex therapeutic areas, this transformation comes at a critical time for the industry. The new identity underscores the company’s commitment to accelerating life-changing therapies to market while strengthening its strategic partnerships with biotech firms globally.
    Full story
  • High Force Research Appoints Chief Commercial Officer to Drive Growth

    Apr 11, 2025, 08:06 AM by
    High Force Research, a leading UK-based provider of specialist chemical R&D and manufacturing services has just appointed Dr. Nathalie Huther as its first-ever Chief Commercial Officer following a recent management buyout. This is a pivotal moment for the company, as it gears up to accelerate growth and deepen its presence in the pharmaceutical, biotech, and specialty chemicals markets. Nathalie brings 15+ years of commercial leadership experience across the chemical and life sciences sectors and will be steering High Force Research’s business development and market expansion strategy.
    Full story
  • Phastar Secures Finalist Spot at 2025 Citeline Awards

    Apr 11, 2025, 08:06 AM by
    Phastar, a global specialist biometrics & data science Contract Research Organization (CRO), has been shortlisted in the ‘CRO Partnership of the Year’ category at the 2025 Citeline Awards for its collaboration with Medicines Development for Global Health (MDGH), a not for profit pharmaceutical company dedicated to the development of affordable medicines for the people who need them most.
    Full story
  • Cellistic Launches Echo™ – NK Platform, a Scalable Solution for Off-the-Shelf Allogeneic Immune Cell Therapies

    Apr 10, 2025, 08:44 AM by
    News from Cellistic, which has launched its new Echo™-NK platform to support the production of off-the-shelf Natural Killer cell therapies. The platform offers a cost-effective, GMP-compliant solution for scaling iPSC-derived NK cells, aimed at treating cancers and autoimmune diseases. It also integrates Cellistic’s STAR-CRISPR and Pulse technologies to help speed up development, with several client projects already in progress.
    Full story
  • Cepheid and Oxford Nanopore Technologies Partner to Advance Automated Sequencing-Based Solutions

    Apr 10, 2025, 08:44 AM by
    Cepheid and Oxford Nanopore Technologies announce new collaboration to develop an integrated sequencing workflow to advance infectious disease analysis.
    Full story
  • Vaxess Announces $9M in Funding for Microarray Drug Delivery Platform

    Apr 10, 2025, 08:44 AM by
    Vaxess Technologies, Inc., a biotech company developing a novel microarray patch technology to transform home delivery of therapies, today announced it has received an additional $9 million in funding. Investors included RA Capital Management and Engine Ventures.
    Full story
  • Large Language Model Predicts, as Well as Explains, Molecular Properties

    Apr 10, 2025, 01:00 AM by User Not Found
    Bio-IT World | Scientists use prior knowledge to solve new problems, and a novel artificial intelligence (AI) system known as LLM4SD (Large Language Model 4 Scientific Discovery) can likewise synthesize knowledge from existing literature. But the method “goes beyond simply repeating information” by interpreting it and coming up with new hypotheses.
    Full story
  • Sphere Bio expands APAC distribution network to strengthen presence in region

    Apr 9, 2025, 08:08 AM by
    Sphere Bio, a leading provider of picodroplet-based microfluidics for functional single-cell analysis and isolation, today announced a significant expansion of its APAC distributor network. This development marks a key milestone in the Company’s global commercial strategy to meet growing demand for its next-generation single-cell analysis platforms.
    Full story